Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

EuroHeartPath EuroHeartPath: Leading Innovation in Cardiovascular Pathways for Improved Patient Outcomes

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 February 2025 to 31 January 2030
Status
Running
EU funding
€15.0m
Total cost
€26.0m
Partners
35 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101194785

What the project is doing

In the project's own words, from its summary on CORDIS.

Cardiovascular diseases (CVD) present a significant public health challenge throughout Europe, being the leading cause of morbidity and a major contributor to mortality. Despite technological advancements and preventative strategies, the burden of CVD remains substantial, and the cardiac care pathways across Europe are inadequately mapped. The overarching goal of the EuroHeartPath consortium is to transform cardiovascular care pathways across the continuum of care.

By adopting a pan-European scope and facilitating cross-country comparisons, EuroHeartPath aims to elucidate how care is organized and delivered, providing deeper insights and identifying best practices for integration with the support of stakeholders, including ESC, WONCA, EUPHA, and EPA.EuroHeartPath will simultaneously conduct 18 pathfinder studies to optimize the personalized early detection, diagnosis, monitoring, and treatment of heart failure, atrial fibrillation, ventricular fibrillation, and coronary disease, with a particular emphasis on prevention.

These studies are categorized into four key areas: 1) novel artificial intelligence (AI) and machine learning applications, such as automated AI analysis of ECGs and Holters, and AI for predicting cardiomyopathies and cardiovascular events; 2) digital health integration, aimed at improving the diagnosis of aortic stenosis and enhancing secondary prevention measures; 3) point-of-care testing, including the use of point-of-care diagnostics in primary practice and ambulances to exclude heart failure; and 4) technology and robotics, encompassing robotic echocardiography and invasive diagnostics in obstructive epicardial coronary artery disease.

EuroHeartPath will create a paradigm shift in the management and treatment of heart disease, offering substantial scientific, societal, and economic impacts across the entire patient health journey with a patient centric approach.

Topics

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator
European Pathway AssociationLeuvenBelgiumParticipant
Insel Gruppe AGBernSwitzerlandAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Deutsches Herzzentrum MunchenMunichGermanyParticipant
Medtronic GmbHMeerbuschGermanyParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Medtronic Iberica SAMadridSpainParticipant
Outcomes'10 SLCastellón de la PlanaSpainParticipant
Servicio Madrileno De SaludMadridSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Philips FranceSuresnesFranceParticipant
Rcf@icpsMassyFranceParticipant
Societe Europeenne De CardiologieBiotFranceParticipant
Amarin Pharmaceuticals Ireland LimitedDublinIrelandParticipant
Boston Scientific Nederland B.V.KerkradeNetherlandsParticipant
Chateau SanteZeistNetherlandsParticipant
Corbotics B.V.DelftNetherlandsParticipant
Cordys Analytics B.V.UtrechtNetherlandsParticipant
European Public Health AssociationUtrechtNetherlandsParticipant
Heart for Health Ict BVAmsterdamNetherlandsParticipant
Iqvia Solutions B.v.AmsterdamNetherlandsParticipant
Novartis Pharma B.V.AmsterdamNetherlandsParticipant
Philips Medical Systems Nederland BVBestNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting Sionsberg Netwerk ZiekenhuisDokkumNetherlandsParticipant
Technische Universiteit EindhovenEindhovenNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Van Vliet Diagnostics BVAlmereNetherlandsParticipant
Viduet Health BVBunnikNetherlandsParticipant
Vintura BVUtrechtNetherlandsParticipant
Stichting Wonca EuropeLjubljanaSloveniaParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomParticipant
London School of Economics and Political ScienceLondonUnited KingdomParticipant
Zeesta LabsLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI